BioSpace News Archive

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reports preliminary financial results for the fourth quarter and full year 2023, ending December 31, 2023.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the publication of previously disclosed results from its Phase 2 study of setmelanotide for the treatment of hypothalamic obesity.

ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces that it will host a conference call at 4pm Eastern time, Wednesday, May 1, 2024 to review the Company’s 2023 full year and fourth quarter, ending December 31, 2023 results.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. financial markets.

Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) (“Justera” or the “Company”) regrettably announces that it has not met the deadline for filing its audited annual financial statements, the accompanying management’s discussion & analysis for the financial year ended December 31, 2023

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2024.

Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024.

Lineage Cell Therapeutics, Inc. is saddened to report the passing of its long-serving Chairman of the Board of Directors, Mr. Alfred D. Kingsley, and offers its deepest condolences to Mr. Kingsley’s family for their loss.

Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fourth quarter and fiscal year 2023, which ended January 31, 2024.

BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission on April 29, 2024.